Re: Volume AND Price!
Finally got around to a bit more DD on this interesting little company hunk. thankyou for mentioning it.
I liked the CEO's Q3 CC sounds like a straight shooter with his honest assessment of corporate strengths and weaknesses for the quarter.How about his 'Lettermanlike'...before the Q/A I'm going to detail the 5 questions I'm asked most frequently in reverse order of frequency to keep your attention until the #1 question.
A lot going on at the Company.Impressive and ambitious business plan to use the generic inhalation/anethesia business to fund and build out conscious monitoring and surgical guidance.15mm/year run rate currently sounds like will ramp in 2007.Manageable burn covered by revenue run and 25mm+ in liquid assets on BS- debt not an issue.Manufacturing capacity--Q2 snafu appears in retrospect to in fact have been an order timing issue and nothing ominous.
Sevoflurane approval near term driver.Analysts had anticipated 2006.Why? What is the basis of this guidance please,anyone? Only a few weeks into 07,stock doesn't appear to be anticipating a significant delay,why didn't approval come in 06-just an FDA(overworked/underpaid)issue?Any reason you could anticipate Sevofl. not being approved?
If they secure approval and can maintain the strategy and timing for bringing the device/therapeutic product to market for conscious sedation this could become a nice size company running between the legs of Baxter and Abbott.
Do you envision these guys being in play at some point in time as conscious monitoring moves toward fruition?
Seems to be hanging in a nice little handle a bit above the 50dma.